EUVIMEDEUVIMED entdecken
Crossref

Cardiovascular outcomes of non-vitamin K antagonist oral anticoagulants among patients with atrial fibrillation

Yik Ching Hung

Eurasian Journal of Medicine and Oncology · 15.07.2026 · 026180195

DOI: 10.36922/ejmo026180195 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Eurasian Journal of Medicine and Oncology, online erschienen am 15.07.2026. Verfasst von Yik Ching Hung.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Non-vitamin K antagonist oral anticoagulants (NOACs) effectively reduce thromboembolic stroke risk in patients with non-valvular atrial fibrillation. Evidence suggested dabigatran may carry a higher risk of myocardial infarction (MI); however, whether NOACs differ in cardiovascular safety remains unclear.

Objectives

To compare three NOACs (dabigatran, rivaroxaban, and apixaban) on the risk of MI and sudden cardiac death.

Methods

Using a database search of the New Territories West Cluster of the Hospital Authority of Hong Kong, 1,161 patients with non-valvular atrial fibrillation taking the three NOACs before December 31, 2017 were recruited into the study. Four comparison cohorts were established among factor Xa inhibitors, dabigatran, rivaroxaban, and apixaban. Cox proportional hazard regression analyses were performed among the weighted population. The primary endpoint included a combined risk of MI and sudden cardiac death. Secondary endpoints were major adverse cardiovascular events (MACE; MI, cardiovascular death, heart failure hospitalization, and stroke), individual MACE components, and fatal bleeding.

Results

Rivaroxaban, apixaban, and factor Xa inhibitors were collectively associated with an insignificant trend of lower combined risk of MI and sudden death compared to dabigatran (hazard ratios of 0.72, 0.58, and 0.67, respectively). There were no significant differences in the comparison of rivaroxaban and apixaban.

Conclusion

Dabigatran was associated with higher but insignificant cardiovascular outcomes. Cardiovascular safety may differ among NOACs in non-valvular atrial fibrillation patients.

Zitieren

APA

Hung, Y. C. (2026). Cardiovascular outcomes of non-vitamin K antagonist oral anticoagulants among patients with atrial fibrillation. Eurasian Journal of Medicine and Oncology, 0(0), 026180195. https://doi.org/10.36922/ejmo026180195

Vancouver

Hung YC. Cardiovascular outcomes of non-vitamin K antagonist oral anticoagulants among patients with atrial fibrillation. Eurasian Journal of Medicine and Oncology. 2026;0(0):026180195. doi:10.36922/ejmo026180195

BibTeX
@article{Hung2026,
  author = {Hung, Yik Ching},
  title = {Cardiovascular outcomes of non-vitamin K antagonist oral anticoagulants among patients with atrial fibrillation},
  journal = {Eurasian Journal of Medicine and Oncology},
  year = {2026},
  volume = {0},
  number = {0},
  pages = {026180195},
  doi = {10.36922/ejmo026180195}
}
Kostenlos starten →